Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 16/06/2008

    Apogenix raises 27.5 million euros

    Apogenix GmbH a biopharmaceutical company announced the closing of its second financing round. dievini Hopp BioTech holding GmbH Co. KG the investment company of SAP co-founder Dietmar Hopp was the main investor.

    https://www.gesundheitsindustrie-bw.de/en/article/news/apogenix-raises-27-5-million-euros
  • Article - 05/11/2009 Dr. Hanswilly Müller operates the blue-framed touch screen of the CLAIR device.

    CLAIR provides new insights

    The human eye is a fascinating organ as well as model for the specialists at Stockach-based Sensovation AG. Their complex optical detection systems are based on CCD and CMOS technologies. However a high-tech sensor is able to recognise much more than many eyes put together.

    https://www.gesundheitsindustrie-bw.de/en/article/news/clair-provides-new-insights
  • Personalised Medicine - 04/05/2017 BigData-Onkologie-doehner_hartmut_eberhardt_kiz.jpg

    Big data make therapy work better

    An international team of researchers has shown for acute myeloid leukaemia (AML) that cancer therapy can be personalised using big data. The authors of the study “believe this paper is a step towards validation of genetic techniques as a route to personalised medicine”.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mit-big-data-genauer-therapieren
  • Press release - 01/12/2009 10262_de.jpg

    Stefan Wiemann elected new spokesman of the German Genome Research Network

    Associate Professor (PD) Dr. Stefan Wiemann of the German Cancer Research Centre (Deutsches Krebsforschungszentrum, DKFZ) has been elected spokesman of the Project Committee of the National Genome Research Network. This funding programme supports projects in medical genome research aimed at fighting relevant widespread diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/stefan-wiemann-elected-new-spokesman-of-the-german-genome-research-network
  • Press release - 04/02/2010 German Cancer Research Centre

    Signalling pathway in cancer cells needs acid: new targets for tailor-made therapies?

    The Wnt signalling pathway plays an important role in embryonic development, in stem cells and also in diseases such as cancer. Some of the individual steps of this signalling pathway are not yet known in detail including in particular the mechanism by which the Wnt protein activates the Wnt receptor during binding. Scientists from the German Cancer Research Centre (Deutsches Krebsforschungszentrum, DKFZ) have now made a substantial contribution…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/signalling-pathway-in-cancer-cells-needs-acid-new-targets-for-tailor-made-therapies
  • Article - 12/12/2011 Core members from the team of Tübingen researchers (from left to right): Dr. Tobias Walker, Dr. rer. nat. Andrea Nolte, Cand. med. C. Makowieki, Prof. Dr. rer. nat. H-P. Wendel.

    siRNA in cancer therapy : Tübingen researchers awarded prize by the German Society of Thoracic Surgery

    Short ribonucleic acid molecules only 21 nucleotides long are providing new impulses for lung cancer treatment. A team of doctors and biologists from the University of Tübingen have been awarded a prize by the German Society of Thoracic Surgery for their research on siRNA.

    https://www.gesundheitsindustrie-bw.de/en/article/news/sirna-in-cancer-therapy-tuebingen-researchers-awarded-prize-by-the-german-society-of-thoracic-surger
  • Article - 30/04/2011 14239_de.jpg

    The DKFZ-ZMBH Alliance

    The strategic alliance between the cell and tumour biology research priority at the German Cancer Research Center and the Center for Molecular Biology at Universität Heidelberg has led to the development of one of the largest centres of basic biomedical research in Germany. The top international profile of this interdisciplinary institution located at the interface between molecular and cellular biology tumour biology and biomedicine is reflected…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-dkfz-zmbh-alliance
  • Article - 16/04/2008

    Roland Schuele - "Research cannot be predicted"

    Professor Roland Schuele from the University Womens Hospital in Freiburg originally studied biochemistry. Nowadays Schuele is researching the development of prostate cancer. During his scientific career he has learnt that research cannot be steered in a particular direction. It develops and we follow it said Schuele who has been able to gain astonishing insights into the molecular processes in tumour cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/roland-schuele-research-cannot-be-predicted
  • Press release - 31/03/2009 Dr. Ronald Koschny (centre), Prof. Dr. Tröger (left), Prorector for Research and Medicine at the University of Heidelberg, and Prof. Dr. Stremmel (right), Medical Director of the Department of Gastroenterology at the University Hospital of Heidelberg, during the award ceremony.

    Cancer researcher from Heidelberg awarded the Dr. Hella Bühler Prize

    Dr. Ronald Koschny assistant doctor in the Department of Gastroenterology at the University Hospital in Heidelberg was awarded the Dr. Hella Bühler Prize. Koschny received the prize which comes with a cheque for 100000 euros for his groundbreaking work on finding new therapies in particular therapies for the treatment of pancreatic cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-researcher-from-heidelberg-awarded-the-dr-hella-buehler-prize
  • Dossier - 13/04/2015 In Germany, young girls can now protect themselves from cervical cancer. (Photo: NCI)

    Boosting the immune system can improve cancer prevention and treatment

    The activation of the body’s immune system to fight cancer is not only a promising therapeutic concept, but is already used in medical practice. The first immunotherapies have been approved and many more are either in the experimental stages or already undergoing clinical testing. Vaccines to prevent certain types of cancer are already being used successfully around the world.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/boosting-the-immune-system-can-improve-cancer-prevention-and-treatment
  • Article - 14/03/2011 Loop model of an EGF molecule with a blue area. Next to the EGF are three tryptophane molecules that differ from each other by the insertion of an N atom at different locations of the molecule.<br />

    Synthesising proteins from non-natural building blocks?

    Dr. Birgit Wiltschi from the University of Freiburg has been awarded funding from the Baden-Württemberg Ministry of Science Research and the Arts under the Biotechnology and Medical Technology Idea Competition for a highly ambitious project she wants to learn how proteins can be modified using non-natural building blocks that will enable the engineered proteins to specifically target receptors on cancer cells amongst other things.

    https://www.gesundheitsindustrie-bw.de/en/article/news/synthesising-proteins-from-non-natural-building-blocks
  • Article - 07/11/2011 Daniel Gebhard, doctoral student at Albstadt-Sigmaringen University

    Daniel Gebhard – a new chapter in the mitochondrial theory of aging

    It has been known for quite some time that skin aging and skin cancer are connected with UV radiation. It is believed that mutations in the mitochondrial DNA are major contributors to aging and cancer, which is why in-depth knowledge about the repair mechanisms of skin cells is essential. Daniel Gebhard, doctoral student at Albstadt-Sigmaringen University, is investigating the repair capacity of mtDNA in different human skin cell types. He is…

    https://www.gesundheitsindustrie-bw.de/en/article/news/daniel-gebhard-a-new-chapter-in-the-mitochondrial-theory-of-aging
  • Article - 09/01/2012 16136_de.jpg

    Nutritional medicine: Can certain foods help treat cancer?

    Researchers at the Centre for Nutritional Medicine (ZEM), a joint institution of the Universities of Hohenheim and Tübingen, are investigating whether and to what extent certain food components can support the treatment of cancer and are hoping to derive scientifically founded dietary recommendations from their findings.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nutritional-medicine-can-certain-foods-help-treat-cancer
  • Press release - 23/07/2009 08704_de.jpg

    Mannheim Medical Centre – leading cancer laboratory and clinical research centre

    Mannheim is the only medical centre in Germany to fulfil the criteria of an affiliated centre of EORTC. According to a recent EORTC report Mannheim is the only German centre that has fulfilled the organisations high quality criteria over the last three years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mannheim-medical-centre-leading-cancer-laboratory-and-clinical-research-centre
  • Press release - 19/11/2010 10529_de.jpg

    Affimed enrols first patients in Phase I Hodgkin’s lymphoma study

    The Heidelberg-based biotech company Affimed Therapeutics AG announced on 15th November 2010 that the first Hodgkin’s lymphoma patients have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. Thus, the “first-in-man” tetravalent, bispecific antibody based on the company’s proprietary RECRUIT-TandAb® antibody technology has entered the clinic.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-enrols-first-patients-in-phase-i-hodgkin-s-lymphoma-study
  • Article - 25/08/2008

    Rare kidney tumour leads the way to a new cancer therapy

    Renal cell carcinoma is a rare disease. In addition, the disease is difficult to treat, and the majority of pharmaceutical companies find the development of new drugs for its treatment too financially risky. Their argument: the market is too small to make up for the high development costs. The Tübingen biotech company immatics was courageous enough to do so and will now be rewarded. The immatics scientists have developed a therapy that not only…

    https://www.gesundheitsindustrie-bw.de/en/article/news/rare-kidney-tumour-leads-the-way-to-a-new-cancer-therapy
  • Article - 27/07/2015 Zender_Lars_Prof.jpg

    Looking for the Achilles’ heel of the tumour

    Although medicines that inhibit the growth of cancer cells are available, the prognosis for patients with solid tumours is generally still rather poor. The reason for this is that tumour cells develop resistance to therapy during treatment, and the tumour can continue to grow. However, tumours are vulnerable – if only more robust medicines were available. Prof. Dr. Lars Zender, senior physician and head of the Division of Translational…

    https://www.gesundheitsindustrie-bw.de/en/article/news/looking-for-the-achilles-heel-of-the-tumour
  • Press release - 18/11/2008

    Oxygen radicals alter immune cells

    Researchers from Heidelberg have discovered that certain oxygen compounds are produced in greater quantities in the body due to cancer or inflammation and that this leads to the alteration of a protein that controls the flexibility and adaptability of certain immune cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/oxygen-radicals-alter-immune-cells
  • Dossier - 20/12/2010 13209_de.jpg

    Environmental toxins: effect and origin

    Environmental toxins, also referred to as xenobiotics, are chemicals that do not occur in biological substance cycles; they are difficult to degrade and often have a toxic effect. Xenobiotic substances are becoming an increasing problem because we are constantly exposed to them and because they slowly but surely poison us. The World Health Organisation (WHO) sees xenobiotic substances as factors that contribute, along with other factors, to the…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/environmental-toxins-effect-and-origin
  • Press release - 03/11/2015 07777_de.jpg

    CureVac raises $110 Million in a private placement

    CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
  • Article - 22/10/2019 AVA LifeScience-Gründer: Ulrich Birsner, Marc Kessemeier, Dr. Marcus Dühren-von Minden (von links nach rechts).

    Using CAR T cells for treating cancer

    After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.

    https://www.gesundheitsindustrie-bw.de/en/article/news/using-car-t-cells-for-treating-cancer
  • Article - 15/11/2008

    Heidelberg students win at the iGEM competition

    The Heidelberg team of 16 students has achieved an outstanding result at the renowned iGEM competition organised by the MIT in Boston. The team won the largest number of prizes with its project Ecolicence to Kill including a gold medal for their scientific work.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-students-win-at-the-igem-competition
  • Article - 21/08/2009 09395_de.jpg

    Patenting and clinical trials go hand in hand

    Back when he was doing his degree thesis at the German Cancer Research Centre in Heidelberg the immunologist Prof. Peter Öhlschläger who now works at the University of Constance laid down the basic principles for developing an artificial gene for the treatment of cervical cancer. Prof. Öhlschläger is currently in the process of filing a patent for DNA vaccines for HPV. In the following interview the scientist says that the greatest challenges are…

    https://www.gesundheitsindustrie-bw.de/en/article/news/patenting-and-clinical-trials-go-hand-in-hand
  • Press release - 10/12/2012 18856_de.jpg

    Sex hormone induces elongation of stem cell telomeres

    The telomere ends of chromosomes become shorter with any cell division round. This is why the lifespan of most cells is limited. One of several exceptions to this rule is the haematopoietic stem cells of the bone marrow. The enzyme telomerase enables them compensate telomere attrition. However defective telomerase function can cause bone marrow failure disorders such as aplastic anaemia amongst others. Prof. Dr. Uwe Martens from the SLK Hospital…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sex-hormone-induces-elongation-of-stem-cell-telomeres
  • Article - 08/04/2013 19469_de.jpg

    The first major cell migration

    It is of crucial importance that cells stick tightly together where their function requires them to do so for example in organs such as the heart and the liver to name but two examples. However it is equally crucial that cells start to migrate at some stage during embryonic development in order to form such organs. Prof. Dr. Wolfgang Driever from the Institute of Biology I at the University of Freiburg and his team have elucidated the molecular…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-first-major-cell-migration

Page 11 / 30

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 30
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search